(Q39683530)

English

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy

scientific article published on September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy (English)

1 reference

Europe PubMed Central

14 September 2017

cholangiocarcinoma

0 references

author name string

Zichen Zhang

1

1 reference

Europe PubMed Central

14 September 2017

Regina A Oyesanya

2

1 reference

Europe PubMed Central

14 September 2017

Deanna J W Campbell

3

1 reference

Europe PubMed Central

14 September 2017

Jorge A Almenara

4

1 reference

Europe PubMed Central

14 September 2017

Jennifer L Dewitt

5

1 reference

Europe PubMed Central

14 September 2017

Alphonse E Sirica

6

1 reference

Europe PubMed Central

14 September 2017

language of work or name

0 references

publication date

1 September 2010

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

52

1 reference

Europe PubMed Central

14 September 2017

3

1 reference

Europe PubMed Central

14 September 2017

975-986

1 reference

Europe PubMed Central

14 September 2017

Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Establishment of a novel rat cholangiocarcinoma cell culture model

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

EGFR and HER2 expression in advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

21 January 2018

Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23773

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.23773

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39683530&oldid=1855566767"